Current impact of seronegative rheumatoid arthritis
Authors:
Z. Hrnčíř
Authors place of work:
II. interní gastroenterologická klinika LF UK a FN, Hradec Králové
Published in the journal:
Čes. Revmatol., 28, 2020, No. 3, p. 152-159.
Category:
Review Article
Summary
Seronegative rheumatoid arthritis (SNRA) is defined as rheumatoid factor (RF) negative and antibodies to citrullinated peptide antigen (ACPA) negative disease. Seropozitive rheumatoid arthritis (SPRA) is defined as RF and/or ACPA positive disease, but also other Abs as valid biomarkers should be used. SNRA pts represent about 20% of RA in general population, largely on late-onset. Minor prevalence of SNRA is not predictive for minor difficulties in clinical practice. Comparative analysis of DMARD (disease modyfying anti-rheumatic drugs) naive SNRA and SPRA pts demonstrated significantly higher values of disease activity using DAS28/ESR (disease activity score/erythrocyte sedimentation rate), incl. 28TJC (tender joint count) and 28SJC (swollen joint count) parameters, and good response to csDMARD (conventional synthetic DMARD) therapy within 2 years follow-up study. Unfortunately, initial activity of SNRA disease is not predictive for easy diagnosis of early SNRA, because exclusion from other possible causes of early seronegative arthritis should be difficult or even actually impossible. In a 10 years. prospective observation study of pts classified as early SNRA (No:435) a reclassification to definite diagnosis was frequent, espec. in relation to polymyalgia rheumatica, psoriatic arthritis, osteoarthritis and gout, but also in a large number of rare conditions (Jaccoud’s arthropathy in systemic lupus erythematosus, ect.) and „orphan“ diseases with mimicry of SNRA. In a long-term 30 years follow up study was demonstrated a significant increased frequency of extra-articular manifestations in SPRA as in SNRA pts, but in SNRA with low risk of rheumatoid pulmonary fibrosis, peripheral/central neuropathy and systemic rheumatoid granulomatosis. Concomitant fibromyalgia, toxicity of long-term DMARD therapy and multimorbidity of SNRA pts should be always evaluated. Early positive identification of SNRA by means of novel perspective biomarkers (antibodies to progranulin, sulphate glycans, ect.) should be a hope for future.
Keywords:
seronegative rheumatoid arthritis – rheumatoid factors – antibodies to citrullinated peptide antigen – antibodies to progranulin – sulphated glycans – score DAS28/ESR – misdiagnosis – concomitant fibromyalgia
Zdroje
1. Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen ICh, Hammer HB, et al. Patients with seronegative RA have more inflammatory aktivity compared with patients with seropositive RA in an inception cohort of DMARD-naive patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis 2017; 76: 341–345.
2. Reguiero C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nuño L, Castaño-Nuñez AL, Villalva A, et al. Specific association of HLA-DRBl*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis. Arthritis Rheumat 2019; 71: 331–339.
3. Shelef M. New relations for old autoantibodies in rheumatoid arthritis. Arthritis Rheumat 2019; 71: 1396–1399.
4. Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka J. Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol 2019; 37: 37–43.
5. Assmann G, Zinke S, Gerling M, Bittenbring JT, Preuss KD, Thurner L. Progranulin-autoantibodies in sera of rheumatoid arthritis patients negative for rheumatoid factor and anti-citrullinated peptide antibodies. Clin Exp Rheumatol 2019; 37 [Epubl ahead of print].
6. Hoffmann MH, Trouw LA, Steiner G. Autoantibodies in rheumatoid arthritis. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (ed.) Rheumatology, 7th ed. Philadelphia: Elsevier 2019; 803–810.
7. Seeling M, Brückner Ch, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease aktivity? Rheumatology 2017; 13: 621–630.
8. Collison J. Seronegative RA-specific biomarkers indentified. Nat Rew Rheumat 2017; 13: 633.
9. Chocholova E, Bertok T, Jane E, Lorencova L, Holazova A, Belicka L, et al. Glycomics meets artificial intelligence – Potential of glycan analysis for identification of seropositive and seronegative rheumatoid arthritis patients revealed. Clin Chim Acta 2018; 481: 49–55.
10. Terao C, Brynedal B, Chen Z, Jiang X, Westerlind H, Hansson M, et al. Distinct HLA associations with rheumatoid arthritis subsets defined by serological subphenotype. Am J Hun Genet 2019; 105: 616–624.
11. Turkcapar N, Demir O, Atli T, Kopuk M, Turgay M, Kinikli G, et al. Late onset rheumatoid arthritis: Clinical and laboratory comparisons with younger onset patients. Arch Geront Geriatr 2006; 42: 225–231.
12. Bengtsson C, Malspeis S, Orellana C, Sparks JA, Contenbader KH, Karlson EW. Association between menopausal factors and the risk of seronegative and seropositive rheumatoid arthritis: results from the nurses’ health studies. Arthritis Care Res 2017; 69: 1676–1684.
13. Coffey CM, David JM, Crowson CS. The impact of gender on time to rheumatoid arthritis classifications: a retrospective analysis of a population-based cohort. Rheumatol Int 2019; 39: 2025–2030.
14. Alemao E, Bao Y, Weinblatt ME, Shadick N. Association of seroposivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs. Arthritis Care Res 2020; 72: 176–183.
15. Vencovský J. Revmatoidní artritida. In: Pavelka K, Vencovský J, Šenolt L, Mann H, Štěpán J, a kol. Revmatologie. 2. vydání, Praha: Maxdorf 2018; 340–360.
16. Choi S, Lee KH. Clinical managment of seronegative and seropositive rheumatoid arthritis: A comparative study. PLoS ONE 2018; 13: e0195550.
17. Bird P, Hall S, Nash P, Connell CA, Kwok K, Witconbe D, et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomized clinical trials of tofacitinib. RMD Open 2019; 5: e000724.
18. Mc Carty DJ, O’Duffy JD, Pearson L, Hunter JB. Remmiting seronegative symmetrical synovitis with pitting edema. RS3 PE syndrome. JAMA 1985; 254: 2763–2767.
19. Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol 1999; 17: 741–744.
20. Hrnčíř Z, Drahošová M, Bradna P, Soukup T, Tomš J. Jaccoudova artropatie u systémového lupus erythematodes. Čes. Revmatol. 2010; 18: 68–72.
21. Glaser C, Rieg S, Wiech T, Scholz Ch, Endres D, Stich O, et al. Whipple’s disease mimicking rheumatoid arthritis can cause misdiagnosis and tratment failure. Orphanet J Hare Dis 2017; 12: 99–107.
22. Shinoda K, Matsui S, Taki H, Hounoki H, Ogawa R, Ishizawa S, et al. Deforming arthropathy in a patient by Stone et al. Arthritis Care Res 2011; 63: 172–174.
23. Schoninger S, Homsi Y, Kreps A, Milojkvovic N. A case of multiple myeloma misdiagnosed as seronegative rheumatoid arthritis and review of relevant literature. Case Rep Rheumatol 2018; 2018: 9746241.
24. Alsaed O, Hadwan H, Khanjar I, Al-Allaf AW. Seronegative bilateral symmetrical inflammatory polyarthritis: think twice before starting immunosuppression. Eur J Case Rep Intern Med 2018; 5: 000895.
25. Chapel H, Haenez M, Misbach S, Snowden N. Essentials in clinical imunology. 6. vydání John Wiley Lmt. 2014; český překlad 1. vydání, Praha: Triton 2018: 108–205.
26. Davaraj NK. The difficult rheumatology diagnosis. Ethiop J Health Sci 2017; 28: 101–102.
27. Syversen SW, Gaarder PI, Goll GL, Odengard S, Haavardsholm EA, Mowickel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67: 212–217.
28. Gadeholt O, Hausotter K, Eberle H, Klink T, Pfeil A. Differing X-ray patterns in seronegative and seropositive rheumatoid arthritis. Clin Rheumatol 2019; 38: 2403–2410.
29. Yurube T, Sumi M, Nishida K, Miyamoto H, Kohyama K, Matsubara T, Miura Y, Hirata H, et al. Accelerated development of cervical spine instabilities in rheumatoid arthritis: A prospective minimum 5-year cohort study. PLoS ONE 2014; 9: e88970.
30. Sahatciu-MekaV, Rexhepi S, Manxihuka-Kerliu S, Rexhepi M. Extra-articular manifestations of seronegative and seropositive rheumatoid arthritis. Bosnian J Basic Med Sci 2010; 10: 26–31.
31. Watrease A, Trabue Ch, Atkinson J, Behrend N. Large endocardial rheumatoid nodules: a case report and review of the literature. J Comm Hosp Intern Med Perspect 2017; 7: 175–177.
32. Lee YC, Lu B, Boire G, Haraoui B, Hitchon CA, Pope JE, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013; 72: 949–954.
33. Tomš J, Soukup T, Bradna P, Hrnčíř Z. Konkomitující fibromyalgie u pacientů s revmatoidní artridiou. Čes. Revmatol. 2009; 17: 120–126.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2020 Číslo 3
Najčítanejšie v tomto čísle
- Current impact of seronegative rheumatoid arthritis
- The role of viruses in the development of autoimmune diseases
- Validation of Czech versions of questionnaires assessing fatigue and physical acti- vity in patients with rheumatic diseases: Fatigue Impact Scale (FIS), Multidimensional Assessment of Fatigue Scale (MAF), Human Activity Profile (HAP)
- Diet in gout – should we reduce the intake of purines?